MSNews updates are on hold until further notice. Sign-up on our mailing list here to be notified when we are back.
Site implementation: Jaspan Consulting
Graphic design:
The MSNews web site is
Reports from Israel state that Teva annouced that it would terminate its trial of Copaxone on primary progressive MS. The trial was supposed to last three years, but interim analysis of the drug is unfavorable.
The story can be found here.